Soluble Ophthalmic Drug Inserts

Maichuk, Yu. F.

doi:10.1016/s0140-6736(75)91481-6

Cited by 21 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An erodible ocular insert was developed for hydrocortisone which was designed to dissolved in 24 h [1]. Soluble ophthalmic drug inserts (SODI) using polymers of polyacrylamide, ethylacrylate and vinyl-pyrrolidone was developed which was beneficial for the eyes and reduces the consumption of drugs used [2].…”

Section: Ocular Insertsmentioning

confidence: 99%

“…Hence, there is a need for development of effective drug delivery strategies for the eye. New drug delivery systems (NDDS), for the anterior segment of the eye includes (a) Ocular inserts (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13), corneal shields (14)(15)(16) and contact lenses (17)(18), which provides controlled delivery of drug to the eye, (b) In situ gelling systems (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29), which provides ease of administration as drops and gets converted to gel form in the eye, thereby providing some sustained effect of drug in the eye, (c) Vesicular systems (30)(31)(32)(33)(34)(35), offers advantages of targeted delivery, bio-*Address correspondence to this author at the Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, New Delhi 110062. India; Tel: 91-9811660105; E-mail: yas2312003@yahoo.com; ysultana@jamiahamdard.ac.in compatibility and freedom from blurring of vision, (d) Mucoadhesive systems (36)(37)(38)(39)(40)(41) provides better retention in the eye, (e) Prodrugs (42)…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Review of Ocular Drug Delivery

Sultana

Jain

Aqil³

et al. 2006

CDD

123

View full text Add to dashboard Cite

Successful treatment of eye diseases requires effective concentration of drug at the eye for sufficient period of time. Conventional ocular drug delivery including eye drops, systemic administration, ophthalmic ointments, is no longer sufficient to combat ocular diseases. This article reviews the constraints with conventional ocular therapy, and explores various novel approaches, to improve the ocular bioavailability of drugs to the anterior chamber of the eye.

show abstract

Section: Ocular Insertsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Review of Ocular Drug Delivery

Sultana

Jain

Aqil³

et al. 2006

CDD

123

View full text Add to dashboard Cite

show abstract

“…Long-term therapeutic drug levels have also been achieved with conjunctival inserts for glaucoma therapy (Lerman 1972) and bacterial conjunctivitis (Maichuk 1967) in man. Collagen film (Bloomfield et af 1978), conjunctival inserts (Lamberts et a1 1978) and medicated hydrophilic contact lenses (Dohlman et af 1972; Praus et a1 1976) have also been used in other animals.…”

Section: Introductionmentioning

confidence: 99%

Ocular inserts for application of drugs to bovine eyes—effects of hydrophilic contact lenses

et al. 1982

View full text Add to dashboard Cite

show abstract

“…unnoticed expulsion from the eye, membrane ruptures etc.). A number of ocular inserts were prepared utilizing different techniques to make soluble, erodible, nonerodible, and hydrogel inserts [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] .…”

Section: Ocular Insertsmentioning

confidence: 99%

Occular Drug Delivery System: An Overview

Ara¹,

Bundela²,

Nimb³

et al. 2017

Curr. Res. Pharm. Sci.

View full text Add to dashboard Cite

Delivery of drugs to the targeted ocular tissues is restricted by various precorneal, dynamic and static ocular barriers. Also, therapeutic drug levels are not maintained for longer duration in target tissues. In the past two decades, ocular drug delivery research acceleratedly advanced towards developing a novel, safe and patient compliant formulation and drug delivery devices/techniques, which may surpass these barriers and maintain drug levels in tissues. Anterior segment drug delivery advances are witnessed by modulation of conventional topical solutions with permeation and viscosity enhancers. Also, it includes development of conventional topical formulations such as suspensions, emulsions and ointments. On the other hand, for posterior ocular delivery, research has been immensely focused towards development of drug releasing devices and nanoformulations for treating chronic vitreoretinal diseases. These occuserts formulations may help to surpass ocular barriers and associated side effects with conventional topical drops. Also, these novel devices and/or formulations are easy to formulate, no/negligibly irritating, possess high precorneal residence time, sustain the drug release, and enhance ocular bioavailability of therapeutics. An update of current research advancement in ocular drug delivery necessitates and helps drug delivery scientists to modulate their think process and develop novel and safe drug delivery strategies.

show abstract

Soluble Ophthalmic Drug Inserts

Cited by 21 publications

References 2 publications

Review of Ocular Drug Delivery

Review of Ocular Drug Delivery

Ocular inserts for application of drugs to bovine eyes—effects of hydrophilic contact lenses

Occular Drug Delivery System: An Overview

Contact Info

Product

Resources

About